Table 4.
Comparison between therapeutic response group and no-response group
| No-response group | Response group | P-value | |
|---|---|---|---|
| Recipient sex, male | 8/11 | 25/50 | .171 |
| Recipient age | 43.6 ± 15.4 | 47.1 ± 11.7 | .389 |
| Donor sex, male | 5/11 | 27/48 | .517 |
| Donor age | 37.1 ± 9.0 | 37.1 ± 12.3 | .994 |
| Hematologic malignancy | .976 | ||
| AML | 3 | 14 | |
| ALL | 4 | 16 | |
| CML | 0 | 1 | |
| NHL | 0 | 2 | |
| MDS | 4 | 17 | |
| Donor type | .167 | ||
| Unrelated | 3 | 25 | |
| Sibling | 5 | 20 | |
| FMT | 3 | 5 | |
| HLA | .717 | ||
| full-match | 7 | 36 | |
| mismatch | 4 | 14 | |
| Stem cell source | 1.000 | ||
| PB | 10 | 41 | |
| BM | 1 | 7 | |
| Cord | 0 | 2 | |
| Time from HSCT to BOS diagnosis, days | 407.0 (272.0–1533.0) | 466.0 (274.3–833.3) | .910 |
| Acute GVHD | 8/11 | 31/50 | .731 |
| Chronic GVHD (except lung) | |||
| Skin | 6/11 | 25/50 | 0.785 |
| Oral | 7/11 | 35/50 | 0.726 |
| Eyes | 9/11 | 27/50 | 0.106 |
| Liver | 2/11 | 8/50 | 1.000 |
| Joint | 0/11 | 3/50 | 1.000 |
| Maximal score of chronic GVHD (except lung)a | 1 (1–2) | 1 (1–2) | 0.227 |
| Systemic steroid | 8/11 | 25/50 | .171 |
| Steroid dose, mg (equivalent dose of prednisolone) | 12.5 (4.4–16.3) | 2.5 (0.0–15.0) | .151 |
| Tacrolimus | 3/11 | 15/50 | 1.000 |
| Cyclosporin | 1/11 | 8/50 | .683 |
| Mycophenolate mofetil | 5/11 | 13/50 | .275 |
| total CAT score, enroll | 10.5 (6.8–16.0) | 16.0 (10.0–20.0) | .083 |
aEach organ was scored as 0, 1, 2 or 3 based on the degree of functional impairment. Data represent the mean ± SD, median (IQR) or n. AML acute myeloid leukemia, ALL acute lymphoblastic leukemia, CML chronic myelogenous leukemia, NHL non-Hodgkin lymphoma, MDS myelodysplastic syndrome, FMT familial-mismatched/haploidentical transplantation, HLA human leukocyte antigen, PB peripheral blood, BM bone marrow, HSCT hematopoietic stem cell transplantation, BOS bronchiolitis obliterans syndrome, GVHD graft-versus-host disease, CAT COPD assessment test